PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-927

Thanks Thrifty , I had noticed this also , so Trialing on a Mouse in Europe? The Company know they require a Mouse Trial and have done so since WEHI 1 and 2 Positive Results, before moving onto Humans... My Question to the BOD was asked in 2020 directly after the Biolabs Positive data "why not move onto an In Vivo Trial , Monkey, Mouse Guiney Pig," now 26 months later PAA are has now signed an agreement to evaluate MPL on a Mouse? Thats the level of Announcement? for the potentially the Most Valuable Treatment on the Planet?

The natural Progression of Scientific Trialing was abandoned by PAA on Covid....
In Vitro1 WEHI 1
In Vitro 2 WEHI 2 if a Mouse Trial was carried out here there would be no Biolabs or Leiden gap year required......
In Vitro 3 Biolabs 360
in Vitro 4 Leiden (9months)
26 months after WEHI 2 data,,,, now we are moving onto an in Vivo Trial with a Mouse,, we are talking Covid , The largest modern day Pandemic, Countries isolating ,Millions of Deaths, Economies Fractured.....

The panacea of an Oral Treatment for Covid is done....... Now Big Pharma are scouring for a Treatment for Long Covid,,, PAA could be back in the race,,,but not at the pace they are currently operating at ...

Phase 2 Human Trial in COVID-19
PharmAust has been identifying clinical centres capable of sourcing patients with the required COVID19 progression and vaccination status. Our search has focussed on Eastern Block European states where there remain a significant number of unvaccinated patients. Encouragingly, three clinical centres in Romania and Bosnia have expressed interest in participating and recruiting sufficient numbers of
qualifying patients for the study.
Next steps include providing protocols for the study and qualification of the identified clinical centres.
We continue to search for contingency sites including in Poland. This critical step of site selection, both
in terms of clinical suitability and patient recruitment numbers, has resulted in a delay in the
commencement of the Phase 1 COVID-19 trial.
Management are stating they couldnt find a suitable clinic or Covid Positive patients during a Global Pandemic

However, this has enabled us to further review the trial rationale and, given the timing of the
commencement of the MND trial, the Board has decided to rely on the MND trial to provide the important
Phase 1 pharmacokinetic (PK) data for both the MND and COVID-19 trials. We believe this will allow
PharmAust to undertake a Phase 2 study in COVID-19 rather than a Phase 1 study. This will facilitate
faster recruitment as we have been advised by the CRO that COVID-19 infected patients generally
prefer participating in a Phase 2 study. This strategy also benefits from a financial saving to PharmAust
of about $1.5 million.
Further, PharmAust has signed an agreement to evaluate MPL in transgenic “humanised” mice, which
will express the receptors that the COVID-19 virus binds to in humans. Efficacy in this anti-viral model
will provide further evidence of the anti-viral effects of MPL.

as above the Quarterly is only 10 days away ,, Cash Position will be critical..... and updates on Patient Numbers recruited for the MND trial